Treatment for Alopecia

Track Code: 
14KU032M
Summary: 

A novel hair growth-enhancing formulation for the treatment of male pattern baldness (androgenic alopecia).

Overview: 

Fifty percent of Caucasian men and women beyond the age of 40 suffer from progressive androgenic alopecia, and while prevalence in Asian, Native American and African-American men is reduced, it is still considerable. The needs of this large market, in addition to those who suffer from chemotherapy-induced alopecia, are not met by current hair loss treatments.

To view a sample of laboratory test results data, including a comparison to commercially available products, download the paper below.

download white paper

Applications: 

Treatment of male pattern baldness (androgenic alopecia).

How it works: 

Novel bioengineered peptide that regulates the Wnt/beta-catenin canonical pathway. Application of the peptide in a topical formulation results in substantially increased hair growth compared to other commercially available products.

Benefits: 

For many people, this novel formulation could prove to be the only effective, affordable means of treating hair loss due to androgenic alopecia or chemotherapy.

Why it is better: 

Current treatments have limited efficacy. In studies, only 15% of patients actually regrow hair following treatment with other products. In direct comparisons, this technology is substantially more effective at accelerating hair growth.

Other Applications: 

Effective treatment for chemotherapy induced alopecia and improves bone-mineral metabolism.

Licensing Associate: 
Aswini Betha, PhD · abetha@ku.edu · 913-588-5713
Subcategory(s): 
Keyword(s): 
Inventor(s): 
Laird Forrest
Shuang Cai
Peter Rowe
Valentin David
Aline Martin
Kenneth Ryan Moulder
Status: 
Patent-Pending